Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Kepley BioSystems
AddedFeb 16, 2024
UpdatedJun 18, 2026
Kepley BioSystems

Kepley BioSystems

Kepley BioSystems: A life sciences start-up in Greensboro, NC, innovating in nanoscience and nanoengineering.

HQ
Greensboro, NC, US
Founded
2013
Overview
Compare
Fundraising
Employees
Website

Kepley BioSystems is a life sciences startup founded in Greensboro, North Carolina, and operates out of Gateway University Research Park in collaboration with the Joint School of Nanoscience and Nanoengineering. The company's core mission is to innovate in the fields of nanoscience and nanoengineering to address critical ecological and medical challenges. Kepley BioSystems focuses on sustainable practices, particularly in the use of the Atlantic horseshoe crab's blue blood for endotoxin testing in the medical industry. Their innovative approaches aim to ensure the viability and well-being of this ecologically important species while meeting industrial demands.

Notable affiliated people include researchers and scientists from the Joint School of Nanoscience and Nanoengineering. Kepley BioSystems has garnered attention for its pioneering methods in horseshoe crab husbandry and bleeding techniques, which have significant implications for both ecological conservation and medical testing. The company’s impact is reflected in its contributions to sustainable practices in biotechnology, potentially setting new standards for industry operations that balance ecological preservation with technological advancement.

Kepley BioSystems - Quick Facts

When was Kepley BioSystems founded?

Kepley BioSystems was founded in 2013.

Where is Kepley BioSystems' headquarters located?

Kepley BioSystems' headquarters is located in Greensboro, NC, US.

When was Kepley BioSystems' last funding round?

Kepley BioSystems' most recent funding round was for $1M (USD) in December 2022.

How much has Kepley BioSystems raised to-date?

As of Dec 13, 2022, Kepley BioSystems has raised a total of $2.6M (USD).

How many employees does Kepley BioSystems have?

Kepley BioSystems has 5 employees as of Feb 4, 2024.

Kepley BioSystems - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
  • Government
Main Product
  • Medical Devices
Tags
  • Biotech
  • Healthtech
  • Research
NAICS
  • 310000Manufacturing
  • 311000Food Manufacturing
SIC
  • 2000Food And Kindred Products
Show 12 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 620000Health Care and Social Assistance
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research